InvestorQ : How is Cipla planning to price its Indian version of Remdesivir for COVID-19 patients?
Crowny Pinto made post

How is Cipla planning to price its Indian version of Remdesivir for COVID-19 patients?

Answer
user profile image
3 months ago


Cipla plans to price its generic version of Remdesivir, the patented drug of Gilead Sciences Inc, at below Rs.5000 per dosage for COVID1-9 patients. Apart from Cipla, Hetero and Jubilant Life Sciences are also approved partners for Gilead. Hetero had announced a similar price range for the 100 mg dosage.

Remdesivir is intravenously administered in hospitals and has been approved for emergency use in severely-ill patients by the FDA and other respective drug regulators in the US, India, Japan and South Korea. Remdesivir is yet to be priced in the United States. Gilead is targeting Remdesivir supply for more than 2 million COVID-19 patients by the end of 2020.

The sales of the drug are estimated between $2 billion and $3 billion for the years 2020 and 2021 assuming average selling price of $1,000 to $2,000 per course.